Business Context and Reporting Period
This Form 8-K Current Report from Bionano Genomics, Inc. (BNGO) covers events occurring on August 4, 2023. The filing details a material modification to the rights of security holders and amendments to the company's Articles of Incorporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a corporate governance report regarding capital structure adjustments.
Material Changes
- Reverse Stock Split: Effective at 5:00 p.m. Eastern Time on August 4, 2023, the Company implemented a 1:10 reverse stock split. Every ten shares of issued and outstanding common stock were automatically converted into one share.
- Trading Adjustments: Common stock began trading on a split-adjusted basis on The Nasdaq Capital Market on August 7, 2023, under the new CUSIP number 09075F305.
- Equity Plan Adjustments: Proportionate adjustments were made to the exercise prices and share counts for outstanding stock options, restricted stock units, and warrants. The number of shares reserved for issuance under equity compensation plans was reduced proportionately.
- Fractional Shares: No fractional shares were issued; stockholders entitled to fractional shares received cash payments in lieu thereof.
- Preferred Stock Elimination: The Company filed a Certificate of Elimination for its Series A Preferred Stock following the automatic redemption of all outstanding shares after the June 14, 2023 Annual Meeting.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard implications of the stock split. The primary operational impact noted is the change in share count and trading symbol details effective August 7, 2023.
Investor Verification Checklist
- Verify the new CUSIP number (09075F305) for the common stock.
- Confirm the adjusted exercise prices and share quantities for any held stock options, RSUs, or warrants.
- Check brokerage statements for cash payments received in lieu of fractional shares.
- Confirm the trading start date for the split-adjusted stock (August 7, 2023).